Published in JAMA on November 15, 2006
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 | NCT01661621
The association of nocturia with incident falls in an elderly community-dwelling cohort. Int J Clin Pract (2010) 1.69
Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology (2013) 1.58
2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J (2010) 1.56
The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol (2013) 1.52
A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. Trials (2008) 1.45
Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep (2013) 1.43
Undisclosed changes in outcomes in randomized controlled trials: an observational study. Ann Fam Med (2009) 1.33
A systematic evaluation of factors associated with nocturia--the population-based FINNO study. Am J Epidemiol (2009) 1.29
Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol (2008) 1.24
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One (2011) 1.16
Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol (2007) 1.14
Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. Korean J Urol (2010) 1.07
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci (2010) 1.05
Male urinary incontinence: prevalence, risk factors, and preventive interventions. Rev Urol (2009) 0.99
Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag (2011) 0.96
Lower urinary tract symptoms in men. BMJ (2014) 0.95
Place of overactive bladder in male lower urinary tract symptoms. World J Urol (2009) 0.93
A modified approach to patient's selection with improved clinical outcomes in sacral nerve modulation. Can Urol Assoc J (2011) 0.91
Performance of the American Urological Association Symptom Index with and without an additional urge incontinence item. Urology (2011) 0.88
A current perspective on geriatric lower urinary tract dysfunction. Korean J Urol (2015) 0.88
Overactive bladder in males. Ther Adv Urol (2009) 0.88
Various treatment options for benign prostatic hyperplasia: A current update. J Midlife Health (2012) 0.86
Medical management of lower urinary tract symptoms. Rev Urol (2009) 0.86
Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine (Baltimore) (2015) 0.86
Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it. Ther Adv Urol (2012) 0.86
Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol (2011) 0.84
Benign prostatic hyperplasia and lower urinary tract symptom guidelines. Can Urol Assoc J (2012) 0.83
Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol (2009) 0.83
Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn Schmiedebergs Arch Pharmacol (2008) 0.81
Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int (2014) 0.81
Oxybutynin extended release for the management of overactive bladder: a clinical review. Drug Des Devel Ther (2009) 0.80
Urologic medications and ophthalmologic side effects: a review. Can Urol Assoc J (2012) 0.80
Extending the rationale of combination therapy to unresponsive erectile dysfunction. Rev Urol (2007) 0.80
Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol (2014) 0.80
Medical treatment of benign prostatic hyperplasia. Rev Urol (2011) 0.79
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract (2007) 0.79
Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol (2016) 0.79
The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging (2009) 0.78
The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol (2010) 0.78
Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study. World J Urol (2014) 0.78
Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. World J Urol (2011) 0.78
Systematic review of therapy for men with overactive bladder. Can Urol Assoc J (2011) 0.76
Management of male urinary incontinence. Indian J Urol (2010) 0.76
'Tamsulosin and Darifenacin' Versus 'Tamsulosin Monotherapy' for 'BPH with Accompanying Overactive Bladder'. J Clin Diagn Res (2015) 0.76
Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms. Clin Interv Aging (2014) 0.76
Treatment of men with lower urinary tract symptoms and overactive bladder. JAMA (2007) 0.75
Treatment of men with lower urinary tract symptoms and overactive bladder. JAMA (2007) 0.75
Treatment of men with lower urinary tract symptoms and overactive bladder. JAMA (2007) 0.75
Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. J Urol (2012) 0.75
Medical management of overactive bladder. Indian J Urol (2010) 0.75
A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. Med Sci Monit (2016) 0.75
Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial. Chin Med J (Engl) (2016) 0.75
New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urol (2016) 0.75
Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol (2012) 0.75
Non-Hormonal treatment of BPH/BOO. Indian J Urol (2014) 0.75
Should an antimuscarinic agent be used for persistent LUTS after treatment with an alpha(1)-blocker? Nat Clin Pract Urol (2008) 0.75
Combination therapies for the management of nocturia and its comorbidities. Res Rep Urol (2015) 0.75
Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice. Prostate Int (2013) 0.75
Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review. Semin Intervent Radiol (2016) 0.75
The dilemma of nocturia. Can Urol Assoc J (2012) 0.75
Nocturia: aetiology and treatment in adults. Nat Rev Urol (2016) 0.75
Therapeutic options in the treatment of benign prostatic hyperplasia. Patient Prefer Adherence (2009) 0.75
Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. Ci Ji Yi Xue Za Zhi (2017) 0.75
Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia. Ci Ji Yi Xue Za Zhi (2017) 0.75
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 2.84
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol (2007) 2.84
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol (2009) 2.76
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol (2006) 2.74
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol (2008) 2.58
Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol (2008) 2.57
Update of AUA guideline on the surgical management of female stress urinary incontinence. J Urol (2010) 2.43
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol (2004) 2.23
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology (2010) 2.19
Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol (2009) 2.06
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology (2005) 2.01
Patient-reported reasons for discontinuing overactive bladder medication. BJU Int (2009) 1.94
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn (2011) 1.93
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc (2011) 1.89
Assessment of basic endoscopic performance using a virtual reality simulator. J Am Coll Surg (2002) 1.86
The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn (2012) 1.82
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology (2003) 1.79
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology (2012) 1.71
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med (2013) 1.71
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol (2007) 1.70
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol (2007) 1.69
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology (2009) 1.61
Age related pathogenesis of nocturia in patients with overactive bladder. J Urol (2007) 1.57
Management of ureteral calculi: a cost comparison and decision making analysis. J Urol (2002) 1.57
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol (2008) 1.55
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol (2005) 1.54
Urodynamic studies in adults: AUA/SUFU guideline. J Urol (2012) 1.51
Large-conductance voltage- and Ca2+-activated K+ channels regulate human detrusor smooth muscle function. Am J Physiol Cell Physiol (2011) 1.50
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int (2007) 1.50
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
A new questionnaire for urinary incontinence diagnosis in women: development and testing. Am J Obstet Gynecol (2005) 1.49
Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int (2009) 1.46
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol (2007) 1.45
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol (2006) 1.42
Implications of the FDA statement on transvaginal placement of mesh: the aftermath. Curr Urol Rep (2014) 1.42
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol (2006) 1.42
Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol (2010) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol (2011) 1.41
Fesoterodine dose response in subjects with overactive bladder syndrome. Urology (2008) 1.41
A feasibility study comparing pharmacist and physician recommendations for sildenafil treatment. J Sex Med (2011) 1.40
Are urologists fairly reimbursed for complex procedures: failure of 22 modifier? Urology (2008) 1.40
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study. Int J Urol (2012) 1.40
Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. Clin Cancer Res (2008) 1.39
Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. BJU Int (2014) 1.39
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate (2004) 1.38
Methods of developing UWIN, the modified American Urological Association symptom score. J Urol (2011) 1.37
Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology (2006) 1.35
Definition and epidemiology of overactive bladder. Urology (2002) 1.35
Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis? J Urol (2005) 1.33
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int (2011) 1.31
Effect of Ramadan fasting on metabolic markers, body composition, and dietary intake in Emiratis of Ajman (UAE) with metabolic syndrome. Diabetes Metab Syndr Obes (2011) 1.31
Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol (2012) 1.30
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate (2007) 1.29
Idiopathic scrotal elephantiasis. Urology (2005) 1.28
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol (2007) 1.27
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol (2011) 1.26
Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int (2011) 1.25
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer (2008) 1.21
Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest (2008) 1.21
Suppression of human detrusor smooth muscle excitability and contractility via pharmacological activation of large conductance Ca2+-activated K+ channels. Am J Physiol Cell Physiol (2012) 1.20
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol (2008) 1.18
Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial. J Urol (2009) 1.18
Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology (2003) 1.18
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol (2008) 1.16
Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology (2006) 1.14
Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology (2006) 1.12
The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. Value Health (2005) 1.11